Liraglutide

利拉鲁肽

Report date: 2026/05/20 20:02:01

Base Information

Drug NameLiraglutide
Drug Alias Name利拉糖肽Liraglutidum利拉鲁肽LiraglutidaLATIN-T1D +[13
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeDepressive Disorder, MajorBinge-Eating Disorder +[36
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2009/06/30
Country/TerritoryFormer Serbia and MontenegroCzechiaBelgium +[52
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active IndicationsSmoking CessationOpioid-Related DisordersOverweight +[12
Inactive IndicationsPost-Acute COVID-19 SyndromeDepressive Disorder, MajorBinge-Eating Disorder +[24

Other Information

ATC CodeA10BJ02